Zobrazeno 1 - 10
of 160
pro vyhledávání: '"11"'
Autor:
Robert F. Dannals, Alvaro A. Ordonez, Zhuo Zhang, Sanjay K. Jain, Hui Wang, Vincent P. DeMarco, Peter J. Tonge, Edward A. Weinstein, Carlton K. K. Lee, Véronique Dartois, Kelly E. Dooley, Daniel P. Holt, Brendan Prideaux, Mariah H. Klunk
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
Autor:
Robert F. Dannals, Alvaro A. Ordonez, Hui Wang, Brendan Prideaux, Sanjay K. Jain, Véronique Dartois, Carlton K. K. Lee, Daniel P. Holt, Peter J. Tonge, Kelly E. Dooley, Edward A. Weinstein, Zhang Zhuo, Vincent P. DeMarco, Mariah H. Klunk
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:5768-5774
Information about intralesional pharmacokinetics (PK) and spatial distribution of tuberculosis (TB) drugs is limited and has not been used to optimize dosing recommendations for new or existing drugs. While new techniques can detect drugs and their m
Autor:
Laura McEntee, William W. Hope, Aaron Dane, Akash Jain, Jennifer Unsworth, Ian A. Critchley, Nicola Farrington, Shampa Das, Nicole Cotroneo, David Melnick, Adam Johnson, Thomas R. Parr, Paul G. Ambrose
Publikováno v:
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Tebipenem pivoxil HBr (TBPM-PI-HBr) is a novel orally bioavailable carbapenem. The active moiety is tebipenem. Tebipenem pivoxil is licensed for use in Japan in children with ear, nose, and throat infections and respiratory infections. The HBr salt w
Autor:
Marguerite L. Monogue, Masakatsu Tsuji, Roger Echols, Sean M. Stainton, David P. Nicolau, Yoshinori Yamano
Publikováno v:
Antimicrobial Agents and Chemotherapy
Herein, we evaluated sustainability of humanized exposures of cefiderocol in vivo over 72 h against pathogens with cefiderocol MICs of 0.5 to 16 μg/ml in the neutropenic murine thigh model. In Acinetobacter baumannii, Pseudomonas aeruginosa, and Ent
Autor:
S. Lalanne, Camille Tron, Florian Lemaitre, Eric Bellissant, Marie-Clémence Verdier, Antoine Petitcollin, S. Nimubona, C. Boglione-Kerrien
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2017, 61 (11), pp.e01166-17. ⟨10.1128/AAC.01166-17⟩
Antimicrobial Agents and Chemotherapy, 2017, 61 (11), pp.e01166-17. ⟨10.1128/AAC.01166-17⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2017, 61 (11), pp.e01166-17. ⟨10.1128/AAC.01166-17⟩
Antimicrobial Agents and Chemotherapy, 2017, 61 (11), pp.e01166-17. ⟨10.1128/AAC.01166-17⟩
Posaconazole is extensively used for prophylaxis for invasive fungal infections. The gastro-resistant tablet formulation has allowed the bioavailability issues encountered with the oral suspension to be overcome. However, overexposure is now frequent
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:6158-6164
This open-label, fixed-sequence, phase 1 study evaluated the pharmacokinetic interaction between maraviroc (MVC) and ritonavir-boosted fosamprenavir (FPV/r) in healthy subjects. In period 1, subjects received 300 mg of MVC twice daily (BID; cohort 1)
Autor:
Susan L. Ford, Shuguang Chen, David A. Margolis, William Spreen, Elizabeth Gould, Herta Crauwels, Stephen C. Piscitelli
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:5472-5477
Dolutegravir (DTG) and GSK1265744 are HIV integrase inhibitors (INIs) in clinical development. The oral formulation of rilpivirine (RPV), a nonnucleoside reverse transcriptase inhibitor (NNRTI), has been approved for treatment-naive HIV infection. Lo
Autor:
Phillip Hay, Sherene S. Min, Yu Lou, Marta Boffito, Graeme Moyle, Ivy Song, Chris Higgs, Elena M. Guerini, Carl Fletcher, Geoffrey J. Yuen
Publikováno v:
Antimicrobial Agents and Chemotherapy. 53:1532-1538
Abacavir (ABC) is administered either at 600 mg once daily (ABC 600 mg QD) or 300 mg twice daily (ABC 300 mg BID) in anti-human immunodeficiency virus (anti-HIV) combination therapy. Although ABC plasma pharmacokinetics following each regimen has bee
Autor:
Jean-Marc Tréluyer, Maïlys De Sousa Mendes, Lambert Assoumou, Déborah Hirt, Gabrielle Lui, Camille Chenevier-Gobeaux, Naïm Bouazza, Frantz Foissac, Marie Suzan-Monti, Jade Ghosn, Christine Rouzioux, Sílvia M. Illamola, Saïk Urien, Jean Paul Viard, Elodie Valade
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2015, 59 (11), pp.6800-6806. ⟨10.1128/aac.01517-15⟩
Antimicrobial Agents and Chemotherapy, 2015, 59 (11), pp.6800-6806. ⟨10.1128/aac.01517-15⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2015, 59 (11), pp.6800-6806. ⟨10.1128/aac.01517-15⟩
Antimicrobial Agents and Chemotherapy, 2015, 59 (11), pp.6800-6806. ⟨10.1128/aac.01517-15⟩
We aimed to describe blood plasma (BP) and seminal plasma (SP) pharmacokinetics of emtricitabine (FTC) in HIV-1-infected men, assess its penetration in the male genital tract, and evaluate its impact on seminal plasma HIV load (spVL) detection. Men f
Autor:
Philippe M. Loiseau, Madeleine Besnard, Cécile Menez, Robert Farinotti, Gillian Barratt, Marion Buyse
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2006, 50, pp.3793-3800. ⟨10.1128/AAC.00837-06⟩
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2006, 50, pp.3793-3800. ⟨10.1128/AAC.00837-06⟩
The aim of this study was to evaluate the potential of a combination of two antileishmanial drugs, miltefosine (HePC) and amphotericin B (AMB), when administered by the oral route. Caco-2 cell monolayers were used as a validated in vitro model of the